-
澳门人巴黎人6123网站BAT2206（乌司奴单抗）注射液上市许可申请获国家药品监督管理局受理
澳门人巴黎人6123网站（上交所代码： 688177 ）是一家位于中国广州，基于科学而创新的全球性生物制药企业，以下简称 “ 澳门人巴黎人6123网站 ” 或 “ 公司 ” 。公司致力于开发新一代创新药和生物类似药，用于治疗肿瘤、自身免疫性...
-
Bio-Thera Solutions Announces the Launch of TOFIDENCE™ (tocilizumab-bavi) in the United States
GUANGZHOU, China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical company developinginnovative therapies and biosimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) intravenousformulation, a biosimilar monoclonal an...
-
Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006, an I
Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof innovative therapies and biosimilars, today announced receiving INDclearance from the US FDA for a phase II Study for BAT8006, an innovative AntibodyDrug Conjugate (ADC) targeting...
FDA Approves Bio-Thera Solutions’ Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
Details